Clovis Oncology Inc (CLVS) 15.04 $CLVS Clovis Oncology

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Clovis Oncology Inc (CLVS) 15.04 $CLVS

Clovis Oncology to Announce Second Quarter 2016 Financial Results and Host Webcast Conference Call on August 8
BusinessWire - Tue Jul 26, 3:05PM CDT
Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its second quarter 2016 financial results on Monday, August 8, 2016, after the close of the U.S. financial markets. Clovis' senior management will host a conference call and live audio webcast at 4:30 p.m. ET that day to discuss the company's results in greater detail.
CLVS: 15.04 (+0.76)

Commit To Buy Clovis Oncology At $10, Earn 25.6% Annualized Using Options
StockOptionsChannel.com - Mon Jun 20, 10:38AM CDT
Investors eyeing a purchase of Clovis Oncology Inc stock, but cautious about paying the going market price of $14.17/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract...
CLVS: 15.04 (+0.76)

How These Biotech's Stocks are Performing? - Clovis Oncology, Illumina, NewLink Genetics and Zafgen
PR Newswire - Thu Jun 09, 7:00AM CDT
Some of the biggest opportunities in the equities market are found in tumultuous industries such as Biotechnology. The segment continues to present a number of remarkable trades as well as potentially good investment that are waiting to be discovered. This morning ActiveWallSt.com features these four biotech stocks in its technical alerts service: Clovis Oncology Inc. (NASDAQ: CLVS), Illumina Inc. (NASDAQ: ILMN), NewLink Genetics Corp. (NASDAQ: NLNK), and Zafgen Inc. (NASDAQ: ZFGN). Learn more about these stocks and receive your complimentary trade alerts at:
ZFGN: 3.17 (+0.13), CLVS: 15.04 (+0.76), NLNK: 10.49 (-0.09), ILMN: 170.65 (+4.30)

Clovis Oncology Presents Data from Phase 2 Studies of Rucaparib in Advanced Ovarian Cancer and Pancreatic Cancer at 2016 ASCO Annual Meeting
BusinessWire - Mon Jun 06, 7:30AM CDT
Clovis Oncology (NASDAQ:CLVS) announced updated phase 2 results from Part 1 of the ongoing ARIEL2 study in patients with advanced ovarian cancer as well as the final results of the RUCAPANC study of rucaparib in pancreatic cancer at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. Rucaparib is the Company's oral, potent, small molecule inhibitor of PARP1, PARP2 and PARP3 currently being developed for the treatment of ovarian cancer, specifically in patients with tumors with BRCA mutations and other DNA repair deficiencies beyond BRCA, including those with high genomic loss of heterozygosity (LOH) also known as "BRCA-like."
CLVS: 15.04 (+0.76)

Clovis Oncology Announces Data Presentations at 2016 ASCO Annual Meeting
BusinessWire - Thu May 19, 3:40PM CDT
--Rolling New Drug Application (NDA) submission for rucaparib for the treatment of patients with advanced ovarian cancer expected to complete during Q2 2016
CLVS: 15.04 (+0.76)

The Shuman Law Firm Investigates Clovis Oncology, Inc.
BusinessWire - Wed May 11, 12:38PM CDT
The Shuman Law Firm announces that it is investigating potential claims against certain officers and directors of Clovis Oncology, Inc. ("Clovis" or the "Company" (Nasdaq: CLVS). Clovis is a Boulder, CO-based biopharmaceutical company that focuses on anti-cancer agents.
CLVS: 15.04 (+0.76)

Clovis reports 1Q loss
Automated Insights - Thu May 05, 4:48PM CDT
BOULDER, Colo. (AP) _ Clovis Oncology Inc. (CLVS) on Thursday reported a loss of $83.4 million in its first quarter.
CLVS: 15.04 (+0.76)

Clovis Oncology Announces Q1 2016 Operating Results and Corporate Update
BusinessWire - Thu May 05, 3:05PM CDT
--Rucaparib MAA submission planned Q4 2016
CLVS: 15.04 (+0.76)

Clovis Oncology to Announce First Quarter 2016 Financial Results and Host Webcast Conference Call on May 5
BusinessWire - Tue Apr 26, 7:00AM CDT
Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its first quarter 2016 financial results on Thursday, May 5, 2016, after the close of the U.S. financial markets. Clovis' senior management will host a conference call and live audio webcast at 4:30 p.m. ET that day to discuss the company's results in greater detail.
CLVS: 15.04 (+0.76)

Market Exclusive Research Weekly Biotech Report
ACCESSWIRE - Mon Apr 18, 8:27AM CDT
NEW YORK, NY / ACCESSWIRE / April 18, 2016 / The week just gone gave us plenty to talk about in the biotech space, with two significant developments - one in oncology and one in a rare genetic growth disorder called acromegaly. Here's what happened, and how things played out as a result.
PGNX: 5.84 (-0.01), CLVS: 15.04 (+0.76), SRPT: 25.91 (+0.63), COLL: 11.86 (-0.27), CHMA: 2.70 (+0.05)

The Zacks Analyst Blog Highlights: Intercept, Clovis, AbbVie, Relypsa and Horizon Pharma
Zacks Equity Research - Zacks Investment Research - Thu Apr 14, 8:30AM CDT
The Zacks Analyst Blog Highlights: Intercept, Clovis, AbbVie, Relypsa and Horizon Pharma
CLVS: 15.04 (+0.76), RLYP: 31.83 (-0.11), HZNP: 18.89 (-0.40), ICPT: 169.72 (-3.31), ABBV: 66.94 (+0.71)

Biotech Stock Roundup: FDA Advisory Panels Say Yes to Intercept, No to Clovis
Arpita Dutt - Zacks Investment Research - Wed Apr 13, 9:02AM CDT
A couple of experimental drugs were reviewed by the FDA's advisory panels with a positive outcome for Intercept (ICPT) while Clovis (CLVS) faces a possible delay in gaining approval for its drug.
VRTX: 98.20 (+1.20), CLVS: 15.04 (+0.76), RLYP: 31.83 (-0.11), HZNP: 18.89 (-0.40), ALXN: 133.50 (+4.90), ICPT: 169.72 (-3.31), ABBV: 66.94 (+0.71)

Why Horizon Pharma, Och-Ziff Capital Management, and Clovis Oncology Slumped Today
Dan Caplinger, The Motley Fool - Motley Fool - Tue Apr 12, 5:58PM CDT
Image: Och-Ziff. Tuesday was a strong day for the stock market, and the primary reason was positive movement in the energy markets. Crude oil prices rose almost $2 per barrel, moving above $42 and carrying a huge swath of energy stocks along with...
CLVS: 15.04 (+0.76), HZNP: 18.89 (-0.40), OZM: 3.35 (-0.01)

Clovis Oncology's Failure Is a Big Win for AstraZeneca
Todd Campbell, The Motley Fool - Motley Fool - Tue Apr 12, 5:41PM CDT
IMAGE SOURCE: FLICKR USER STOCKMONKEYS.COM. Following a disastrous drubbing by the Food and Drug Administration's key advisory committee, the future for Clovis Oncology 's once-promising non-small cell lung cancer drug rociletinib is up in the...
CLVS: 15.04 (+0.76), AZN: 33.84 (-0.30)

Clovis Oncology Provides Update on FDA Oncologic Drugs Advisory Committee Meeting to Review Rociletinib for Treatment of Advanced T790M-Positive Mutant Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer
BusinessWire - Tue Apr 12, 12:52PM CDT
Clovis Oncology, Inc. (NASDAQ: CLVS) announced today that the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) met to discuss approval of the New Drug Application (NDA) for rociletinib, an investigational therapy for the treatment of patients with mutant epidermal growth factor receptor (EGFR) non-small cell lung cancer (NSCLC) who have been previously treated with an EGFR-targeted therapy and have the T790M mutation.
CLVS: 15.04 (+0.76)

Trading of Clovis Oncology, Inc. Common Stock Halted
BusinessWire - Tue Apr 12, 6:04AM CDT
Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that NASDAQ has halted trading of the Company's common stock. The U.S. Food and Drug Administration's (FDA) Oncologic Drugs Advisory Committee (ODAC) is meeting this morning to discuss the company's New Drug Application (NDA) for rociletinib for the treatment of patients with mutant epidermal growth factor receptor (EGFR) non-small cell lung cancer (NSCLC) who have been previously treated with an EGFR-targeted therapy and have the EGFR T790M mutation.
CLVS: 15.04 (+0.76)

Clovis Hits 52-week Low Post Rociletinib Briefing Documents
Zacks Equity Research - Zacks Investment Research - Mon Apr 11, 2:45PM CDT
Clovis Oncology's (CLVS) shares touched a 52-week low with the FDA raising concerns related to the lung cancer treatment, rociletinib, in its briefing documents.
EBS: 30.97 (-2.42), CLVS: 15.04 (+0.76), ANIK: 50.64 (+0.72)

Weekly Biotech Report Covering Opko Health Inc (NYSE:OPK) Intercept Pharmaceuticals (NASDAQ:ICPT) Gilead Sciences, Inc (NASDAQ:GILD) Clovis Oncology, Inc. (NASDAQ:CLVS) Chiasma, Inc. (NASDAQ:CHMA)
ACCESSWIRE - Mon Apr 11, 10:49AM CDT
NEW YORK, NY / ACCESSWIRE / April 11, 2016 / This Market Exclusive report covers all major biotech news from last week as well as any major news expected this week on these companies.
OPK: 10.07 (+0.12), CLVS: 15.04 (+0.76), GILD: 80.46 (+0.99), CTLT: 25.77 (+0.23), ICPT: 169.72 (-3.31), CHMA: 2.70 (+0.05)

FDA Posts Briefing Documents for Advisory Committee Meeting to Review Clovis Oncology's Rociletinib for Treatment of Advanced T790M-Positive Mutant Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer
BusinessWire - Fri Apr 08, 7:43AM CDT
Clovis Oncology, Inc. (NASDAQ: CLVS) announced today that the U.S. Food and Drug Administration (FDA) posted briefing materials in advance of the Oncologic Drugs Advisory Committee (ODAC) meeting to discuss accelerated approval of the New Drug Application (NDA) for rociletinib, an investigational therapy for the treatment of patients with mutant epidermal growth factor receptor (EGFR) non-small cell lung cancer (NSCLC) who have been previously treated with an EGFR-targeted therapy and have the T790M mutation.
CLVS: 15.04 (+0.76)

Clovis Oncology (CLVS) Catches Eye: Stock Moves 6% Higher
Zacks Equity Research - Zacks Investment Research - Thu Apr 07, 7:15AM CDT
Clovis Oncology, Inc. (CLVS) shares rose 6% in the last trading session.
CLVS: 15.04 (+0.76), ANIK: 50.64 (+0.72)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

MISUMI Americas Expands, Ventures into New Horizons

Updated Category News Views 119

Marking New Territory in Monterrey MISUMI Americas is planting a new flag down in Monterrey, Mexico, with a sprawling 45,000-square-foot facility. This isn't just another expansion; it's a strategic move that's bound to shake things up in the manufacturing sector south of the border. When you've got a player like MISUMI widening their footprint, it catches the eye. Why?...

Continue Reading
Neil deGrasse Tyson Headlines HIMSS27 with Cosmic Insights

Updated Category News Views 188

celebrated science communicator, is set to close out the HIMSS27 conference with a keynote that's bound to leave a lasting impression. It's a fitting intersection of stars and stethoscopes, as the astrophysicist brings his expansive lens to the nitty-gritty of healthcare innovation. Splicing Science with Storytelling Folks, this ain't your standard healthcare gathering....

Continue Reading
Sovereign Crown Vault's Auction Draws Numismatic Collectors

Updated Category News Views 82

A Legendary Auction with Three Generations of Passion Coins, eh? They might just be small metallic disks to the untrained eye, but these suckers tell stories that stretch beyond any bank ledger. Sovereign Crown Vault LLC knows this, and they’re gearing up for quite the show on November 22, 2026. Their Holiday Season Kickoff Spectacular is about to lure in collectors...

Continue Reading
Ranger and Smith Unveil Tea-Infused Chocolate Bar

Updated Category News Views 88

Fresh Collaborations in Portland's Culinary Scene Ah, the sweet crossover in Portland's food scene is once again in the spotlight with a new entry that's sure to titillate taste buds. Ranger Chocolate Co. and Steven Smith Teamaker are at it again, rolling out a delectable creation that merges the poetic elegance of tea with the indulgent richness of chocolate. Welcome,...

Continue Reading
Gary Brecka's Longevity Centers Set to Launch with Impact

Updated Category News Views 114

A Footprint of Longevity in the Making It's not every day you see a name like Daymond John, of Shark Tank fame, getting his hands into the business of human longevity. But here we are, with Gary Brecka's Ultimate Longevity Center (ULC) getting ready to open its first centers come January 2027, in Arizona, Colorado, Florida, and Southern California. More than 300 U.S....

Continue Reading
SGRY Acquisition Under Scrutiny: Fairness Questioned

Updated Category News Views 185

Questions Hover Over SGRY Acquisition Here's a real jaw-dropper for you. Surgery Partners, Inc. (NASDAQ: SGRY) is getting clocks cleaned in a fairness probe over its acquisition terms. If you thought this ride was smooth, think again—Levi & Korsinsky, LLP has put the brakes on any such assumptions, launching an investigation that’s sure to raise some eyebrows. What's...

Continue Reading
MacKenzie-Childs Grinds Into Spotlight with Oprah's Nod

Updated Category News Views 69

Oprah's Golden Touch: 30 Years Strong Every year, there are a few select spots that brands covet like a hawk on a rabbit hunt. Getting on Oprah’s 'Favorite Things' list is surely one of them. Just like that, the MacKenzie-Childs Electric Salt and Pepper Grinder Set has muscled its way into the 2026 selection. Spare me the bells and whistles; this is like hitting the...

Continue Reading
Norris Lake's New Kayak Fleet Propels Tourism Efforts

Updated Category News Views 120

Norris Lake Doubles Down on Water Adventures The winds of change are paddling through Norris Dam State Park as they've launched a new fleet of shiny kayaks, hoping to lure more adventure seekers into the heart of Tennessee. These ain't just boats; they're part of a bigger play by local tourism honchos hungry to pump some adrenaline—and dollars—back into the area. A...

Continue Reading
S&P Global's Bold $2 Billion Debt Offering Details

Updated Category News Views 80

Drilling Down into S&P Global's Debt Move S&P Global's throwing its hat in the ring with a colossal $2 billion debt offering. Now, they aren't just setting it on the table — they're notably carving it up into three chunks. You’ve got $750 million at 5.600% that comes due in 2031, $600 million at 5.800% for 2034, and $650 million at a 6.000% rate maturing in 2036....

Continue Reading
AdMaven's Mave AI: Revolutionizing Campaign Management

Updated Category News Views 125

Taking the Tedious Out of Advertising You've got to love it when technology actually makes life easier, rather than more complicated. AdMaven's latest fancy toy, the AI assistant Mave, is promising just that. It's designed to take the heavy lifting off advertisers' shoulders, especially the day-to-day grind of tweaking ad settings and monitoring performance. If you've...

Continue Reading

Top 5 Most Recently Viewed Articles

Preliminary Ratings Issued by KBRA for Upstart Securitization Trust

Updated Category News Views 388

Preliminary Ratings by KBRA for Upstart Securitization Trust 2024-1 KBRA recently assigned preliminary ratings to the three classes of notes issued by Upstart Securitization Trust 2024-1, also known as UPST 2024-1. This securitization involves a notable value of $208.001 million, primarily revolving around unsecured consumer loans. Details of the Ratings The assigned...

Continue Reading
Alchemy Pay Expands With Mississippi License Milestone

Updated Category News Views 247

Alchemy Pay's Latest Regulatory Push Well, here's something to chew on—Alchemy Pay, that stalwart in the fiat-crypto payment arena, just nabbed a Money Transmitter License down in Mississippi. Good move, because this means they've got their hands now in 20 states across the U.S. Quite a feat for a company out of Hong Kong looking to make waves in the regulatory ocean....

Continue Reading
Optimi Health Steps Up with Microdose Psilocybin

Updated Category News Views 27

New Horizons in the World of Psychedelics Optimi Health has just dropped a noteworthy update, and it's not something to ignore if you're keeping an eye on the psychedelic sector. They're rolling out microdose psilocybin products — a move that’s poised to stir the waters in clinical research. With dosages standardized at 1mg and 2mg, Optimi is targeting the need for...

Continue Reading
PowerBank Corporation Sees Stock Surge After Funding News

Updated Category News Views 111

PowerBank Corporation Stock Surge PowerBank Corporation (NASDAQ: SUUN) experienced significant stock gains recently, particularly on Wednesday. This rise came after the company announced an initial payment of $4 million for its solar projects, including Elmira, Jordan Road 1, and Jordan Road 2. This financial boost has attracted investor interest and propelled the stock...

Continue Reading
Lazard's Q3 2026: Surging Revenue, Waning Net Income

Updated Category News Views 88

Breaking Down the Numbers Lazard just dropped its Q3 2026 earnings report, and you can smell both optimism and caution in the air. Sure, $814 million in net revenue isn’t anything to sneeze at, especially when it’s a neat 9% jump from last year’s $748 million. Adjusted figures were a whisker away at $805 million. But dig deeper, and things get a tad less rosy—net...

Continue Reading